Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Lilly's fourth-quarter earnings, released before the market opened Thursday, surpassed analysts' expectations by millions.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

Lilly expects full-year earnings in the range of $22.50 to $24 per share, with revenue in the range of $58 billion to $61 billion. This story was generated by Automated Insights ( ...

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Eli Lilly and Company has announced the appointment of Winselow Tucker as President and General Manager for Lilly India, ...